<DOC>
	<DOCNO>NCT01632306</DOCNO>
	<brief_summary>Purpose phase I/II study test well LY2090314 work combination different chemotherapy treat participant metastatic pancreatic cancer .</brief_summary>
	<brief_title>A Study LY2090314 Chemotherapy Participants With Metastatic Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Metastatic pancreatic cancer metastasis amenable biopsy Willingness provide tissue blood sample research purpose Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 0 1 History islet cell , acinar cell , cystadenocarcinomas Prior cytotoxic chemotherapy metastatic disease , except prior gemcitabine FOLFIRINOX ( 5FU + leucovorin + irinotecan + oxaliplatin ) Radiation therapy , immunotherapy biologic therapy &lt; 28 day prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>